MXCT

Business Context and Reporting Period

Company: MaxCyte, Inc. (MXCT)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: MaxCyte is a global life sciences company providing cell engineering solutions, primarily through its proprietary Flow Electroporation technology. The company generates revenue from the sale of instruments, processing assemblies (PAs), consumables, licenses, and assay services. It operates as a single reportable segment focused on cell engineering technology.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 15% ($1.24 million) for the three months ended June 30, 2026, compared to the same period in 2025. Core revenue (instruments, PAs, licenses, services) dropped 21%, driven by lower PA and license sales. This was partially offset by a 149% increase in Strategic Platform License (SPL) milestone and royalty revenue.
• Expense Reductions: Operating expenses decreased significantly due to a workforce reduction plan executed in September 2025.
  • R&D: Decreased 32% ($2.02 million) quarter-over-quarter.
  • Sales & Marketing: Decreased 42% ($2.42 million) quarter-over-quarter.
  • G&A: Decreased 10% ($0.82 million) quarter-over-quarter, despite a $1.58 million charge for abandoned asset acquisition costs.
• Net Loss Improvement: Net loss narrowed to $8.87 million for the quarter (from $12.36 million in the prior year) and $13.62 million for the six-month period (from $22.62 million in the prior year), primarily due to reduced operating expenses.
• Share Repurchases: The company repurchased 1.31 million shares for $1.48 million during the six months ended June 30, 2026, under a $10 million program authorized in May 2026.

Outlook, Risks, and Unusual Items

• Liquidity: As of June 30, 2026, the company held $15.04 million in cash and $90.65 million in short-term investments. Management believes these resources are sufficient to fund operations for at least the next 12 months.
• Unusual Items:
  • Asset Acquisition Charge: A $1.58 million charge was recorded in G&A expenses for previously capitalized costs related to an asset acquisition that was discontinued.
  • Impairment: A $0.63 million impairment charge was recorded for laboratory equipment no longer in use.
  • Inventory Reserve: Increased charges to inventory reserves were noted to write down expiring PA inventory to net realizable value.
• Risks: The company remains dependent on the capital availability and program progress of its SPL partners. Revenue is subject to variability due to the timing of clinical milestones. The company continues to incur net losses and may require additional financing in the future.
• Subsequent Event: Following the period end, the company repurchased an additional 2.95 million shares for $4.02 million.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the ~$105 million in liquid assets against the current burn rate (~$12.8 million operating cash outflow for six months) to confirm the 12-month liquidity assertion.
• Core Revenue Trends: Monitor the 21% decline in core revenue to determine if the reduction in workforce and marketing spend is impacting long-term growth potential.
• SPL Milestone Dependency: Assess the sustainability of revenue growth given the heavy reliance on variable milestone and royalty payments from partners, which are non-recurring and unpredictable.
• Share Repurchase Impact: Evaluate the impact of the $10 million buyback program on remaining liquidity and the company's ability to fund future R&D or acquisitions.
• Inventory Valuation: Review the increasing inventory reserves for expiring PAs to ensure gross margins are not being artificially propped up by write-downs in future periods.